Home>>Signaling Pathways>> Microbiology & Virology>> SARS-CoV>>Remdesivir (GS-5734)

Remdesivir (GS-5734) (Synonyms: GS-5734)

Catalog No.GC32223

Remdesivir (GS-5734) (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively.

Products are for research use only. Not for human use. We do not sell to patients.

Remdesivir (GS-5734) Chemical Structure

Cas No.: 1809249-37-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$131.00
In stock
5mg
$99.00
In stock
10mg
$163.00
In stock
50mg
$495.00
In stock
100mg
$711.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Remdesivir is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for ARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells.

Remdesivir (GS-5734) is a potent antiviral agent. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h[1].

References
[1]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18.

Reviews

Review for Remdesivir (GS-5734)

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Remdesivir (GS-5734)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.